Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Li, Wei ^a   Zhao, Xiaoxu ^a   Du, Bin ^a   Li, Xin ^a   Liu, Shuhao ^a   Yang, Xiao Yan ^a   Ding, Hui ^a   Yang, Wende ^a   Pan, Fan ^a   Wu, Xiaobo ^a   Qin, Li ^a   Pan, Yunlong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG CARRIER; ENDOSTATIN; FLUOROURACIL; GOLD; NANOPARTICLE; RECOMBINANT PROTEIN;

ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; FEMALE; LIVER CELL CARCINOMA; LIVER TUMOR; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TREATMENT OUTCOME; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENDOSTATINS; FEMALE; FLUOROURACIL; GOLD; HETEROGRAFTS; LIVER NEOPLASMS; MICE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84979948864     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30619     Document Type: Article

References (45)

1. Folkman, J. Tumor angiogenesis: Therapeutic implications. The New England journal of medicine 285, 1182-1186, doi: 10.1056/NEJM197111182852108 (1971).
2. Weiss, A. et al. Angiostatic treatment prior to chemo-or photodynamic therapy improves anti-Tumor efficacy. Scientific reports 5, 8990, doi: 10.1038/srep08990 (2015).
3. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932-936, doi: 10.1038/nature04478 (2005).
4. Roodink, I. & Leenders, W. P. J. Targeted therapies of cancer Angiogenesis inhibition seems not enough. Cancer letters 299, 1-10, doi: 10.1016/j.canlet.2010.09.004 (2010).
5. Paez-Ribes, M. et al. Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell 15, 220-231, doi: 10.1016/j.ccr.2009.01.027 (2009).
6. Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology 3, 24-40, doi: 10.1038/ncponc0403 (2006).
7. Ebos, J. M. L. et al. Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis. Cancer Cell 15, 232-239, doi: 10.1016/j.ccr.2009.01.021 (2009).
8. Chatterjee, S. et al. Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer. Cancer Research 74, 2816-2824, doi: 10.1158/0008-5472.CAN-13-2986 (2014).
9. Weiss, A. et al. Angiostatic treatment prior to chemo-or photodynamic therapy improves anti-Tumor efficacy. Scientific reports 5, doi: Artn 899010.1038/Srep08990 (2015)
10. Claes, A. et al. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Molecular Cancer Therapeutics 7, 71-78, doi: 10.1158/1535-7163.MCT-07-0552 (2008).
11. Zhu, H. et al. Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia. Scientific reports 5, 14503, doi: 10.1038/srep14503 (2015).
12. Zhuo, W. et al. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. The Journal of pathology 222, 249-260, doi: 10.1002/path.2760 (2010).
13. Brideau, G. et al. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 67, 11528-11535, doi: 10.1158/0008-5472.CAN-07-1458 (2007).
14. Ling, Y. et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochemical and biophysical research communications 361, 79-84, doi: 10.1016/j. bbrc.2007.06.155 (2007).
15. Pan, Y. et al. Inhibition effects of gold nanoparticles on proliferation and migration in hepatic carcinoma-conditioned HUVECs. Bioorganic & medicinal chemistry letters 24, 679-684, doi: 10.1016/j.bmcl.2013.11.045 (2014).
16. Ghosh, P., Han, G., De, M., Kim, C. K. & Rotello, V. M. Gold nanoparticles in delivery applications. Advanced drug delivery reviews 60, 1307-1315, doi: 10.1016/j.addr.2008.03.016 (2008).
17. Iosin, M., Toderas, F., Baldeck, P. L. & Astilean, S. Study of protein-gold nanoparticle conjugates by fluorescence and surfaceenhanced Raman scattering. J Mol Struct 924, 196-200, doi: 10.1016/j.molstruc.2009.02.004 (2009).
18. Ernsting, M. J., Murakami, M., Roy, A. & Li, S. D. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. Journal of Controlled Release 172, 782-794, doi: 10.1016/j.jconrel.2013.09.013 (2013).
19. Baban, D. F. & Seymour, L. W. Control of tumour vascular permeability. Advanced drug delivery reviews 34, 109-119 (1998).
20. Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proceedings of the National Academy of Sciences of the United States of America 95, 4607-4612 (1998).
21. Li, Y. et al. Cell and nanoparticle transport in tumour microvasculature: The role of size, shape and surface functionality of nanoparticles. Interface focus 6, 20150086, doi: 10.1098/rsfs.2015.0086 (2016).
22. Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31, 2205-2218, doi: 10.1200/JCO.2012.46.3653 (2013).
23. Ruan, S. B. et al. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials 37, 425-435, doi: 10.1016/j.biomaterials.2014.10.007 (2015).
24. Du, R. et al. HIF1 alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206-220, doi: 10.1016/j.ccr.2008.01.034 (2008).
25. Sullivan, R. & Graham, C. H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metast Rev 26, 319-331, doi: 10.1007/s10555-007-9062-2 (2007).
26. Jain, R. K. Normalizing tumor vasculature with anti-Angiogenic therapy: A new paradigm for combination therapy. Nat Med 7, 987-989, doi: Doi 10.1038/Nm0901-987 (2001)
27. Folkman, J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312, 594-607, doi: 10.1016/j. yexcr.2005.11.015 (2006).
28. OReilly, M. S. et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
29. Xiao, L. J. et al. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis. Cancer letters 359, 148-154, doi: 10.1016/j.canlet.2015.01.012 (2015).
30. Mitra, P., Chakraborty, P. K., Saha, P., Ray, P. & Basu, S. Antibacterial efficacy of acridine derivatives conjugated with gold nanoparticles. Int J Pharmaceut 473, 636-643, doi: 10.1016/j.ijpharm.2014.07.051 (2014).
31. Tabakovic, A., Kester, M. & Adair, J. H. Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications. Wires Nanomed Nanobi 4, 96-112, doi: 10.1002/wnan.163 (2012).
32. Patra, A. et al. Component-Specific Analysis of Plasma Protein Corona Formation on Gold Nanoparticles Using Multiplexed Surface Plasmon Resonance. Small 12, 1174-1182, doi: 10.1002/smll.201501603 (2016).
33. Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A. & McNeil, S. E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Advanced drug delivery reviews 61, 428-437, doi: 10.1016/j.addr.2009.03.009 (2009).
34. Raza, A., Franklin, M. J. & Dudek, A. Z. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85, 593-598, doi: 10.1002/ajh.21745 (2010).
35. Goel, S. et al. Normalization of the Vasculature for Treatment of Cancer and Other Diseases. Physiol Rev 91, 1071-1121, doi: 10.1152/physrev.00038.2010 (2011).
36. Meng, M. B. et al. Pericytes: A double-edged sword in cancer therapy. Future Oncol 11, 169-179, doi: 10.2217/fon.14.123 (2015).
37. Greenberg, J. I. et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809-U101, doi: 10.1038/nature07424 (2008).
38. Augustin, H. G., Koh, G. Y., Thurston, G. & Alitalo, K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Bio 10, 165-177, doi: 10.1038/nrm2639 (2009).
39. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732, doi: 10.1038/nrc1187 (2003).
40. Liu, Q. Z. et al. Genetic targeting of sprouting angiogenesis using Apln-CreER. Nature communications 6, doi: Artn 602010.1038/Ncomms7020 (2015)
41. Palazon, A., Aragones, J., Morales-Kastresana, A., de Landazuri, M. O. & Melero, I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clinical cancer research: An official journal of the American Association for Cancer Research 18, 1207-1213, doi: 10.1158/1078-0432.CCR-11-1591 (2012).
42. Abdollahi, A. et al. Endostatins antiangiogenic signaling network. Mol Cell 13, 649-663 (2004).
43. Zhang, L. et al. Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol Biol Rep 39, 89-95, doi: 10.1007/s11033-011-0713-6 (2012).
44. Macpherson, G. R. et al. Anti-Angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Molecular Cancer Therapeutics 2, 845-854 (2003).
45. Joshi, H. M., Bhumkar, D. R., Joshi, K., Pokharkar, V. & Sastry, M. Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir: The ACS journal of surfaces and colloids 22, 300-305, doi: 10.1021/la051982u (2006).